Role of vitamin e in the treatment of alzheimer’s disease: Evidence from animal models

International Journal of Molecular Sciences

Volumn 18, Issue 12, 2017, Pages

  Gugliandolo, Agnese ^a   Bramanti, Placido ^a   Mazzon, Emanuela ^a  

^a IRCCS CENTRO NEUROLESI BONINO PULEJO   (Italy)

Author keywords

Alzheimer s disease; Tocopherol; Tocotrienol; Vitamin E

Indexed keywords

ALPHA TOCOPHEROL; ALPHA TOCOTRIENOL; AMYLOID BETA PROTEIN; ASCORBIC ACID; CHOLESTEROL; FOLIC ACID; GLUTATHIONE; GLUTATHIONE DISULFIDE; GLUTATHIONE PEROXIDASE; NICOTINIC RECEPTOR ALPHA4BETA2; PHOSPHOLIPID TRANSFER PROTEIN; REACTIVE OXYGEN METABOLITE; SUPEROXIDE DISMUTASE; TAU PROTEIN; ANTIOXIDANT;

ALPHA TOCOPHEROL DEFICIENCY; ALZHEIMER DISEASE; AMNESIA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; APOPTOSIS; BRAIN INJURY; COGNITIVE DEFECT; HORMONE METABOLISM; LIPID PEROXIDATION; MAPK SIGNALING; MEMORY DISORDER; MORTALITY; NEUROFIBRILLARY TANGLE; NEUROPROTECTION; NEUROTOXICITY; NEUROTRANSMISSION; NITROSYLATION; NONHUMAN; OXIDATIVE STRESS; PROTEIN PHOSPHORYLATION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; SPATIAL LEARNING; UPREGULATION; VITAMIN SUPPLEMENTATION; ANIMAL; CLINICAL TRIAL (TOPIC); COMBINATION DRUG THERAPY; DIETARY SUPPLEMENT; DISEASE MODEL; DRUG EFFECT; HUMAN; METABOLISM; PATHOLOGY; PRECLINICAL STUDY; PROTEINOSIS; TREATMENT OUTCOME;

ALZHEIMER DISEASE; AMYLOID BETA-PEPTIDES; ANIMALS; ANTIOXIDANTS; CLINICAL TRIALS AS TOPIC; DIETARY SUPPLEMENTS; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; DRUG THERAPY, COMBINATION; HUMANS; OXIDATIVE STRESS; PROTEIN AGGREGATION, PATHOLOGICAL; REACTIVE OXYGEN SPECIES; TAU PROTEINS; TREATMENT OUTCOME; VITAMIN E;

EID: 85035151188     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18122504     Document Type: Review

References (97)

1. Tarawneh, R., Holtzman, D.M. The clinical problem of symptomatic Alzheimer disease and mild cognitive impairment. Cold Spring Harb. Perspect. Med. 2012, 2, a006148.
2. Sadigh-Eteghad, S., Sabermarouf, B., Majdi, A., Talebi, M., Farhoudi, M., Mahmoudi, J. Amyloid-β: A crucial factor in Alzheimer’s disease. Med. Princ. Pract. 2015, 24, 1-10.
3. Bloom, G.S. Amyloid-β and tau: The trigger and bullet in Alzheimer disease pathogenesis. JAMA Neurol. 2014, 71, 505-508.
4. Masters, C.L., Bateman, R., Blennow, K., Rowe, C.C., Sperling, R.A., Cummings, J.L. Alzheimer’s disease. Nat. Rev. Dis. Primers 2015, 1, 15056.
5. Tanzi, R.E. The genetics of alzheimer disease. Cold Spring Harb. Perspect. Med. 2012, 2.
6. Nalivaeva, N.N., Turner, A.J. The amyloid precursor protein: A biochemical enigma in brain development, function and disease. FEBS Lett. 2013, 587, 2046-2054.
7. Swomley, A.M., Forster, S., Keeney, J.T., Triplett, J., Zhang, Z., Sultana, R., Butterfield, D.A. Aβ, oxidative stress in Alzheimer disease: Evidence based on proteomics studies. Biochim. Biophys. Acta 2014, 1842, 1248-1257.
8. Takahashi, R.H., Nagao, T., Gouras, G.K. Plaque formation and the intraneuronal accumulation of β-amyloid in Alzheimer’s disease. Pathol. Int. 2017, 67, 185-193.
9. Sanabria-Castro, A., Alvarado-Echeverria, I., Monge-Bonilla, C. Molecular pathogenesis of Alzheimer’s disease: An update. Ann. Neurosci. 2017, 24, 46-54.
10. Butterfield, D.A., Swomley, A.M., Sultana, R. Amyloid β-peptide (1-42)-induced oxidative stress in alzheimer disease: Importance in disease pathogenesis and progression. Antioxid. Redox Signal. 2013, 19, 823-835.
11. Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler, F., Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., et al. Intraneuronal Aβ42 accumulation in human brain. Am. J. Pathol. 2000, 156, 15-20.
12. Stewart, K.L., Radford, S.E. Amyloid plaques beyond Aβ: A survey of the diverse modulators of amyloid aggregation. Biophys. Rev. 2017, 9, 405-419.
13. Yankner, B.A., Lu, T. Amyloid β-protein toxicity and the pathogenesis of alzheimer disease. J. Biol. Chem. 2009, 284, 4755-4759.
14. Tomic, J.L., Pensalfini, A., Head, E., Glabe, C.G. Soluble fibrillar oligomer levels are elevated in alzheimer’s disease brain and correlate with cognitive dysfunction. Neurobiol. Dis. 2009, 35, 352-358.
15. Tamagno, E., Bardini, P., Guglielmotto, M., Danni, O., Tabaton, M. The various aggregation states of β-amyloid 1-42 mediate different effects on oxidative stress, neurodegeneration, and bace-1 expression. Free Radic. Biol. Med. 2006, 41, 202-212.
16. Zhao, Y., Zhao, B. Oxidative stress and the pathogenesis of alzheimer’s disease. Oxid. Med. Cell. Longev. 2013, 2013, 316523.
17. Pappolla, M.A., Chyan, Y.J., Omar, R.A., Hsiao, K., Perry, G., Smith, M.A., Bozner, P. Evidence of oxidative stress and in vivo neurotoxicity of β-amyloid in a transgenic mouse model of alzheimer’s disease: A chronic oxidative paradigm for testing antioxidant therapies in vivo. Am. J. Pathol. 1998, 152, 871-877.
18. Sponne, I., Fifre, A., Drouet, B., Klein, C., Koziel, V., Pincon-Raymond, M., Olivier, J.-L., Chambaz, J., Pillot, T. Apoptotic neuronal cell death induced by the non-fibrillar amyloid-β peptide proceeds through an early reactive oxygen species-dependent cytoskeleton perturbation. J. Biol. Chem. 2003, 278, 3437-3445.
19. Jang, J.-H., Surh, Y.-J. β-amyloid induces oxidative DNA damage and cell death through activation of c-jun N terminal kinase. Ann. N. Y. Acad. Sci. 2002, 973, 228-236.
20. De Felice, F.G., Velasco, P.T., Lambert, M.P., Viola, K., Fernandez, S.J., Ferreira, S.T., Klein, W.L. Aβ oligomers induce neuronal oxidative stress through an N-methyl-D-aspartate receptor-dependent mechanism that is blocked by the alzheimer drug memantine. J. Biol. Chem. 2007, 282, 11590-11601.
21. Leuner, K., Schutt, T., Kurz, C., Eckert, S.H., Schiller, C., Occhipinti, A., Mai, S., Jendrach, M., Eckert, G.P., Kruse, S.E., et al. Mitochondrion-derived reactive oxygen species lead to enhanced amyloid β formation. Antioxid. Redox Signal. 2012, 16, 1421-1433.
22. Stancu, I.-C., Vasconcelos, B., Terwel, D., Dewachter, I. Models of β-amyloid induced tau-pathology: The long and “folded” road to understand the mechanism. Mol. Neurodegener. 2014, 9, 51.
23. De Felice, F.G., Wu, D., Lambert, M.P., Fernandez, S.J., Velasco, P.T., Lacor, P.N., Bigio, E.H., Jerecic, J., Acton, P.J., Shughrue, P.J., et al. Alzheimer’s disease-type neuronal tau hyperphosphorylation induced by a β oligomers. Neurobiol. Aging 2008, 29, 1334-1347.
24. Mietelska-Porowska, A., Wasik, U., Goras, M., Filipek, A., Niewiadomska, G. Tau protein modifications and interactions: Their role in function and dysfunction. Int. J. Mol. Sci. 2014, 15, 4671-4713.
25. Jiang, Q. Natural forms of vitamin E: Metabolism, antioxidant, and anti-inflammatory activities and their role in disease prevention and therapy. Free Radic. Biol. Med. 2014, 72, 76-90.
26. Galli, F., Azzi, A., Birringer, M., Cook-Mills, J.M., Eggersdorfer, M., Frank, J., Cruciani, G., Lorkowski, S., Ozer, N.K. Vitamin E: Emerging aspects and new directions. Free Radic. Biol. Med. 2017, 102, 16-36.
27. Shahidi, F., de Camargo, A.C. Tocopherols and tocotrienols in common and emerging dietary sources: Occurrence, applications, and health benefits. Int. J. Mol. Sci. 2016, 17, 1745.
28. Niki, E. Role of vitamin E as a lipid-soluble peroxyl radical scavenger: In vitro and in vivo evidence. Free Radic. Biol. Med. 2014, 66, 3-12.
29. Wong, R.S.Y., Radhakrishnan, A.K. Tocotrienol research: Past into present. Nutr. Rev. 2012, 70, 483-490.
30. Meganathan, P., Fu, J.Y. Biological properties of tocotrienols: Evidence in human studies. Int. J. Mol. Sci. 2016, 17, 1682.
31. Di Donato, I., Bianchi, S., Federico, A. Ataxia with vitamin E deficiency: Update of molecular diagnosis. Neurol. Sci. 2010, 31, 511-515.
32. Ulatowski, L.M., Manor, D. Vitamin E and neurodegeneration. Neurobiol. Dis. 2015, 84, 78-83.
33. Ulatowski, L., Parker, R., Warrier, G., Sultana, R., Butterfield, D.A., Manor, D. Vitamin E is essential for purkinje neuron integrity. Neuroscience 2014, 260, 120-129.
34. Yokota, T., Igarashi, K., Uchihara, T., Jishage, K., Tomita, H., Inaba, A., Li, Y., Arita, M., Suzuki, H., Mizusawa, H., et al. Delayed-onset ataxia in mice lacking α-tocopherol transfer protein: Model for neuronal degeneration caused by chronic oxidative stress. Proc. Natl. Acad. Sci. USA 2001, 98, 15185-15190.
35. Yoshida, Y., Itoh, N., Hayakawa, M., Habuchi, Y., Saito, Y., Tsukamoto, Y., Cynshi, O., Jishage, K.-I., Arai, H., Niki, E. The role of α-tocopherol in motor hypofunction with aging in α-tocopherol transfer protein knockout mice as assessed by oxidative stress biomarkers. J. Nutr. Biochem. 2010, 21, 66-76.
36. Fukui, K., Nakamura, K., Shirai, M., Hirano, A., Takatsu, H., Urano, S. Long-term vitamin E-deficient mice exhibit cognitive dysfunction via elevation of brain oxidation. J. Nutr. Sci. Vitaminol. 2015, 61, 362-368.
37. Boyd-Kimball, D., Sultana, R., Mohmmad-Abdul, H., Butterfield, D.A. Rodent Aβ(1-42) exhibits oxidative stress properties similar to those of human Aβ(1-42): Implications for proposed mechanisms of toxicity. J. Alzheimers Dis. 2004, 6, 515-525.
38. Yatin, S.M., Varadarajan, S., Butterfield, D.A. Vitamin E prevents alzheimer’s amyloid β-peptide (1-42)-induced neuronal protein oxidation and reactive oxygen species production. J. Alzheimers Dis. 2000, 2, 123-131.
39. Tamagno, E., Parola, M., Guglielmotto, M., Santoro, G., Bardini, P., Marra, L., Tabaton, M., Danni, O. Multiple signaling events in amyloid β-induced, oxidative stress-dependent neuronal apoptosis. Free Radic. Biol. Med. 2003, 35, 45-58.
40. Qi, X.-L., Xiu, J., Shan, K.-R., Xiao, Y., Gu, R., Liu, R.-Y., Guan, Z.-Z. Oxidative stress induced by β-amyloid peptide(1-42) is involved in the altered composition of cellular membrane lipids and the decreased expression of nicotinic receptors in human SH-SY5Y neuroblastoma cells. Neurochem. Int. 2005, 46, 613-621.
41. Fukui, K., Takatsu, H., Shinkai, T., Suzuki, S., Abe, K., Urano, S. Appearance of amyloid β-like substances and delayed-type apoptosis in rat hippocampus ca1 region through aging and oxidative stress. J. Alzheimers Dis. 2005, 8, 299-309.
42. Scimemi, A., Meabon, J.S., Woltjer, R.L., Sullivan, J.M., Diamond, J.S., Cook, D.G. Amyloid-β1-42 slows clearance of synaptically released glutamate by mislocalizing astrocytic GLT-1. J. Neurosci. 2013, 33, 5312-5318.
43. Mazur-Kolecka, B., Golabek, A., Nowicki, K., Flory, M., Frackowiak, J. Amyloid-β impairs development of neuronal progenitor cells by oxidative mechanisms. Neurobiol. Aging 2006, 27, 1181-1192.
44. Rota, C., Rimbach, G., Minihane, A.-M., Stoecklin, E., Barella, L. Dietary vitamin E modulates differential gene expression in the rat hippocampus: Potential implications for its neuroprotective properties. Nutr. Neurosci. 2005, 8, 21-29.
45. Pratico, D., Uryu, K., Leight, S., Trojanoswki, J.Q., Lee, V.M. Increased lipid peroxidation precedes amyloid plaque formation in an animal model of alzheimer amyloidosis. J. Neurosci. 2001, 21, 4183-4187.
46. Resende, R., Moreira, P.I., Proenca, T., Deshpande, A., Busciglio, J., Pereira, C., Oliveira, C.R. Brain oxidative stress in a triple-transgenic mouse model of alzheimer disease. Free Radic. Biol. Med. 2008, 44, 2051-2057.
47. Yamada, K., Tanaka, T., Han, D., Senzaki, K., Kameyama, T., Nabeshima, T. Protective effects of idebenone and alpha-tocopherol on β-amyloid-(1-42)-induced learning and memory deficits in rats: Implication of oxidative stress in β-amyloid-induced neurotoxicity in vivo. Eur. J. Neurosci. 1999, 11, 83-90.
48. Jhoo, J.H., Kim, H.-C., Nabeshima, T., Yamada, K., Shin, E.-J., Jhoo, W.-K., Kim, W., Kang, K.-S., Jo, S.A., Woo, J.I. β-amyloid (1-42)-induced learning and memory deficits in mice: Involvement of oxidative burdens in the hippocampus and cerebral cortex. Behav. Brain Res. 2004, 155, 185-196.
49. Nishida, Y., Yokota, T., Takahashi, T., Uchihara, T., Jishage, K.-I., Mizusawa, H. Deletion of vitamin E enhances phenotype of alzheimer disease model mouse. Biochem. Biophys. Res. Commun. 2006, 350, 530-536.
50. Nishida, Y., Ito, S., Ohtsuki, S., Yamamoto, N., Takahashi, T., Iwata, N., Jishage, K.-I., Yamada, H., Sasaguri, H., Yokota, S., et al. Depletion of vitamin E increases amyloid β accumulation by decreasing its clearances from brain and blood in a mouse model of alzheimer disease. J. Biol. Chem. 2009, 284, 33400-33408.
51. Desrumaux, C., Pisoni, A., Meunier, J., Deckert, V., Athias, A., Perrier, V., Villard, V., Lagrost, L., Verdier, J.-M., Maurice, T. Increased amyloid-β peptide-induced memory deficits in phospholipid transfer protein (pltp) gene knockout mice. Neuropsychopharmacology 2013, 38, 817-825.
52. Sung, S., Yao, Y., Uryu, K., Yang, H., Lee, V.M.Y., Trojanowski, J.Q., Pratico, D. Early vitamin E supplementation in young but not aged mice reduces Aβ levels and amyloid deposition in a transgenic model of alzheimer’s disease. FASEB J. 2004, 18, 323-325.
53. Nakashima, H., Ishihara, T., Yokota, O., Terada, S., Trojanowski, J.Q., Lee, V.M.Y., Kuroda, S. Effects of _-tocopherol on an animal model of tauopathies. Free Radic. Biol. Med. 2004, 37, 176-186.
54. Feijoo, C., Campbell, D.G., Jakes, R., Goedert, M., Cuenda, A. Evidence that phosphorylation of the microtubule-associated protein tau by SAPK4/p38δ at Thr50 promotes microtubule assembly. J. Cell Sci. 2005, 118, 397-408.
55. Giraldo, E., Lloret, A., Fuchsberger, T., Vina, J. Aβ and tau toxicities in alzheimer’s are linked via oxidative stress-induced p38 activation: Protective role of vitamin E. Redox Biol. 2014, 2, 873-877.
56. Sun, A., Liu, M., Nguyen, X.V., Bing, G. P38 map kinase is activated at early stages in Alzheimer’s disease brain. Exp. Neurol. 2003, 183, 394-405.
57. Veinbergs, I., Mallory, M., Sagara, Y., Masliah, E. Vitamin E supplementation prevents spatial learning deficits and dendritic alterations in aged apolipoprotein E-deficient mice. Eur. J. Neurosci. 2000, 12, 4541-4546.
58. Ishihara, Y., Itoh, K., Mitsuda, Y., Shimada, T., Kubota, T., Kato, C., Song, S.Y., Kobayashi, Y., Mori-Yasumoto, K., Sekita, S., et al. Involvement of brain oxidation in the cognitive impairment in a triple transgenic mouse model of alzheimer’s disease: Noninvasive measurement of the brain redox state by magnetic resonance imaging. Free Radic. Res. 2013, 47, 731-739.
59. Garcia-Alloza, M., Dodwell, S.A., Meyer-Luehmann, M., Hyman, B.T., Bacskai, B.J. Plaque-derived oxidative stress mediates distorted neurite trajectories in the alzheimer mouse model. J. Neuropathol. Exp. Neurol. 2006, 65, 1082-1089.
60. Yang, S.-G., Wang, W.-Y., Ling, T.-J., Feng, Y., Du, X.-T., Zhang, X., Sun, X.-X., Zhao, M., Xue, D., Yang, Y., etal. α-tocopherol quinone inhibits β-amyloid aggregation and cytotoxicity, disaggregates preformed fibrils and decreases the production of reactive oxygen species, no and inflammatory cytokines. Neurochem. Int. 2010, 57, 914-922.
61. Wang, S.-W., Yang, S.-G., Liu, W., Zhang, Y.-X., Xu, P.-X., Wang, T., Ling, T.-J., Liu, R.-T. α-tocopherol quinine ameliorates spatial memory deficits by reducing β-amyloid oligomers, neuroinflammation and oxidative stress in transgenic mice with Alzheimer’s disease. Behav. Brain Res. 2016, 296, 109-117.
62. Uryu, K., Laurer, H., McIntosh, T., Pratico, D., Martinez, D., Leight, S., Lee, V.M.Y., Trojanowski, J.Q. Repetitive mild brain trauma accelerates Aβ deposition, lipid peroxidation, and cognitive impairment in a transgenic mouse model of alzheimer amyloidosis. J. Neurosci. 2002, 22, 446-454.
63. Conte, V., Uryu, K., Fujimoto, S., Yao, Y., Rokach, J., Longhi, L., Trojanowski, J.Q., Lee, V.M.Y., McIntosh, T.K., Pratico, D. Vitamin E reduces amyloidosis and improves cognitive function in Tg2576 mice following repetitive concussive brain injury. J. Neurochem. 2004, 90, 758-764.
64. Tiwari, V., Kuhad, A., Bishnoi, M., Chopra, K. Chronic treatment with tocotrienol, an isoform of vitamin E, prevents intracerebroventricular streptozotocin-induced cognitive impairment and oxidative-nitrosative stress in rats. Pharmacol. Biochem. Behav. 2009, 93, 183-189.
65. Ibrahim, N.F., Yanagisawa, D., Durani, L.W., Hamezah, H.S., Damanhuri, H.A., Wan Ngah, W.Z., Tsuji, M., Kiuchi, Y., Ono, K., Tooyama, I. Tocotrienol-rich fraction modulates amyloid pathology and improves cognitive function in Abpp/ps1 mice. J. Alzheimers Dis. 2017, 55, 597-612.
66. Yao, Y., Chinnici, C., Tang, H., Trojanowski, J.Q., Lee, V.M., Pratico, D. Brain inflammation and oxidative stress in a transgenic mouse model of alzheimer-like brain amyloidosis. J. Neuroinflamm. 2004, 1, 21.
67. Niki, E. Interaction of ascorbate and α-tocopherol. Ann. N. Y. Acad. Sci. 1987, 498, 186-199.
68. Harrison, F.E., Allard, J., Bixler, R., Usoh, C., Li, L., May, J.M., McDonald, M.P. Antioxidants and cognitive training interact to affect oxidative stress and memory in app/psen1 mice. Nutr. Neurosci. 2009, 12, 203-218.
69. Figueiredo, C.P., Bicca, M.A., Latini, A., Prediger, R.D.S., Medeiros, R., Calixto, J.B. Folic acid plus α-tocopherol mitigates amyloid-β-induced neurotoxicity through modulation of mitochondrial complexes activity. J. Alzheimers Dis. 2011, 24, 61-75.
70. Thakurta, I.G., Banerjee, P., Bagh, M.B., Ghosh, A., Sahoo, A., Chattopadhyay, S., Chakrabarti, S. Combination of N-acetylcysteine, α-lipoic acid and α-tocopherol substantially prevents the brain synaptosomal alterations and memory and learning deficits of aged rats. Exp. Gerontol. 2014, 50, 19-25.
71. Thakurta, I.G., Chattopadhyay, M., Ghosh, A., Chakrabarti, S. Dietary supplementation with N-acetyl cysteine, α-tocopherol and α-lipoic acid reduces the extent of oxidative stress and proinflammatory state in aged rat brain. Biogerontology 2012, 13, 479-488.
72. Sinha, M., Bir, A., Banerjee, A., Bhowmick, P., Chakrabarti, S. Multiple mechanisms of age-dependent accumulation of amyloid β protein in rat brain: Prevention by dietary supplementation with N-acetylcysteine, alpha-lipoic acid and alpha-tocopherol. Neurochem. Int. 2016, 95, 92-99.
73. Dong, Y., Chen, X., Liu, Y., Shu, Y., Chen, T., Xu, L., Li, M., Guan, X. Do low-serum vitamin E levels increase the risk of alzheimer disease in older people? Evidence from a meta-analysis of case-control studies. Int. J. Geriatr. Psychiatry 2017.
74. Jimenez-Jimenez, F.J., de Bustos, F., Molina, J.A., Benito-Leon, J., Tallon-Barranco, A., Gasalla, T., Orti-Pareja, M., Guillamon, F., Rubio, J.C., Arenas, J., et al. Cerebrospinal fluid levels of _-tocopherol (vitamin E) in alzheimer’s disease. J. Neural Trans. 1997, 104, 703-710.
75. Mangialasche, F., Kivipelto, M., Mecocci, P., Rizzuto, D., Palmer, K., Winblad, B., Fratiglioni, L. High plasma levels of vitamin E forms and reduced alzheimer’s disease risk in advanced age. J. Alzheimers Dis. 2010, 20, 1029-1037.
76. Sano, M., Ernesto, C., Thomas, R.G., Klauber, M.R., Schafer, K., Grundman, M., Woodbury, P., Growdon, J., Cotman, C.W., Pfeiffer, E., et al. A controlled trial of selegiline, α-tocopherol, or both as treatment for alzheimer’s disease. The alzheimer’s disease cooperative study. N. Engl. J. Med. 1997, 336, 1216-1222.
77. Dysken, M.W., Sano, M., Asthana, S., Vertrees, J.E., Pallaki, M., Llorente, M., Love, S., Schellenberg, G.D., McCarten, J.R., Malphurs, J., et al. Effect of vitamin E and memantine on functional decline in Alzheimer disease: The TEAM-AD VA cooperative randomized trial. JAMA 2014, 311, 33-44.
78. Farina, N., Isaac, M.G.E.K.N., Clark, A.R., Rusted, J., Tabet, N. Vitamin E for alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst. Rev. 2012, 11, CD002854.
79. Petersen, R.C., Thomas, R.G., Grundman, M., Bennett, D., Doody, R., Ferris, S., Galasko, D., Jin, S., Kaye, J., Levey, A., et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N. Engl. J. Med. 2005, 352, 2379-2388.
80. Lloret, A., Badia, M.-C., Mora, N.J., Pallardo, F.V., Alonso, M.-D., Vina, J. Vitamin E paradox in alzheimer’s disease: It does not prevent loss of cognition and may even be detrimental. J. Alzheimers Dis. 2009, 17, 143-149.
81. Farina, N., Llewellyn, D., Isaac, M.G.E.K.N., Tabet, N. Vitamin E for alzheimer’s dementia and mild cognitive impairment. Cochrane Database Syst. Rev. 2017, 4, CD002854.
82. Kryscio, R.J., Abner, E.L., Caban-Holt, A., Lovell, M., Goodman, P., Darke, A.K., Yee, M., Crowley, J., Schmitt, F.A. Association of antioxidant supplement use and dementia in the prevention of Alzheimer’s disease by vitamin E and selenium trial (preadvise). JAMA Neurol. 2017, 74, 567-573.
83. Miller, E.R., III, Pastor-Barriuso, R., Dalal, D., Riemersma, R.A., Appel, L.J., Guallar, E. Meta-analysis: High-dosage vitamin E supplementation may increase all-cause mortality. Ann. Intern. Med. 2005, 142, 37-46.
84. Pavlik, V.N., Doody, R.S., Rountree, S.D., Darby, E.J. Vitamin E use is associated with improved survival in an alzheimer’s disease cohort. Dement. Geriatr. Cogn. Disord. 2009, 28, 536-540.
85. Abner, E.L., Schmitt, F.A., Mendiondo, M.S., Marcum, J.L., Kryscio, R.J. Vitamin E and all-cause mortality: A meta-analysis. Curr. Aging Sci. 2011, 4, 158-170.
86. Devore, E.E., Grodstein, F., van Rooij, F.J.A., Hofman, A., Stampfer, M.J., Witteman, J.C.M., Breteler, M.M.B. Dietary antioxidants and long-term risk of dementia. Arch. Neurol. 2010, 67, 819-825.
87. Morris, M.C., Evans, D.A., Bienias, J.L., Tangney, C.C., Wilson, R.S. Vitamin E and cognitive decline in older persons. Arch. Neurol. 2002, 59, 1125-1132.
88. Morris, M.C., Evans, D.A., Tangney, C.C., Bienias, J.L., Wilson, R.S., Aggarwal, N.T., Scherr, P.A. Relation of the tocopherol forms to incident alzheimer disease and to cognitive change. Am. J. Clin. Nutr. 2005, 81, 508-514.
89. Morris, M.C., Schneider, J.A., Li, H., Tangney, C.C., Nag, S., Bennett, D.A., Honer, W.G., Barnes, L.L. Brain tocopherols related to alzheimer’s disease neuropathology in humans. Alzheimers Dement. 2015, 11, 32-39.
90. Kang, J.H., Cook, N., Manson, J., Buring, J.E., Grodstein, F. A randomized trial of vitamin E supplementation and cognitive function in women. Arch. Intern. Med. 2006, 166, 2462-2468.
91. Engelhart, M.J., Geerlings, M.I., Ruitenberg, A., van Swieten, J.C., Hofman, A., Witteman, J.C.M., Breteler, M.M.B. Dietary intake of antioxidants and risk of alzheimer disease. JAMA 2002, 287, 3223-3229.
92. Basambombo, L.L., Carmichael, P.-H., Cote, S., Laurin, D. Use of vitamin E and C supplements for the prevention of cognitive decline. Ann. Pharmacother. 2017, 51, 118-124.
93. Zandi, P.P., Anthony, J.C., Khachaturian, A.S., Stone, S.V., Gustafson, D., Tschanz, J.T., Norton, M.C., Welsh-Bohmer, K.A., Breitner, J.C.S., Cache County Study Group. Reduced risk of alzheimer disease in users of antioxidant vitamin supplements: The cache county study. Arch. Neurol. 2004, 61, 82-88.
94. Grodstein, F., Chen, J., Willett, W.C. High-dose antioxidant supplements and cognitive function in community-dwelling elderly women. Am. J. Clin. Nutr. 2003, 77, 975-984.
95. Fillenbaum, G.G., Kuchibhatla, M.N., Hanlon, J.T., Artz, M.B., Pieper, C.F., Schmader, K.E., Dysken, M.W., Gray, S.L. Dementia and Alzheimer’s disease in community-dwelling elders taking vitamin C and/or vitamin E. Ann. Pharmacother. 2005, 39, 2009-2014.
96. O’Brien, J.T., Holmes, C., Jones, M., Jones, R., Livingston, G., McKeith, I., Mittler, P., Passmore, P., Ritchie, C., Robinson, L., et al. Clinical practice with anti-dementia drugs: A revised (third) consensus statement from the British association for psychopharmacology. J. Psychopharmacol. 2017, 31, 147-168.
97. Cervantes, B., Ulatowski, L.M. Vitamin E and alzheimer’s disease-is it time for personalized medicine? Antioxidants 2017, 6.